Ligand Pharmaceuticals Inc
LGND169.830USD
+4.420+2.67%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
3.30BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ligand Pharmaceuticals Inc Unternehmen
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Unternehmensinformationen
BörsenkürzelLGND
Name des UnternehmensLigand Pharmaceuticals Inc
IPO-datumNov 18, 1992
CEOMr. Todd C. Davis
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeNov 18
Addresse555 Heritage Drive, Suite 200
StadtJUPITER
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl33458
Telefon18585507500
Websitehttps://www.ligand.com/
BörsenkürzelLGND
IPO-datumNov 18, 1992
CEOMr. Todd C. Davis
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
44.37K
-1.04%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.29K
+31.26%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
44.37K
-1.04%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Andere
12.02M
26.52%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Andere
12.02M
26.52%
Aktionärsstatistik
Aktualisiert: Sat, Aug 23
Aktualisiert: Sat, Aug 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Global Advisors (US)
3.83%
Andere
61.85%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Global Advisors (US)
3.83%
Andere
61.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
58.71%
Investment Advisor/Hedge Fund
37.72%
Individual Investor
2.35%
Pension Fund
1.63%
Research Firm
1.22%
Bank and Trust
0.45%
Hedge Fund
0.45%
Sovereign Wealth Fund
0.11%
Insurance Company
0.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
2023Q1
528
16.47M
96.50%
-1.33M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
2.67M
13.86%
-26.33K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
2.05M
10.63%
-29.89K
-1.44%
Mar 31, 2025
Janus Henderson Investors
1.03M
5.33%
+12.53K
+1.23%
Mar 31, 2025
Macquarie Investment Management
906.23K
4.7%
+21.85K
+2.47%
Mar 31, 2025
State Street Global Advisors (US)
727.13K
3.77%
-16.51K
-2.22%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
744.93K
3.86%
+21.91K
+3.03%
Mar 31, 2025
Congress Asset Management Company, LLP
642.71K
3.33%
+21.23K
+3.42%
Mar 31, 2025
Stephens Investment Management Group, LLC
607.22K
3.15%
-5.56K
-0.91%
Mar 31, 2025
Chicago Capital, LLC
554.52K
2.87%
+2.93K
+0.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
464.45K
2.41%
+26.01K
+5.93%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
Invesco Pharmaceuticals ETF
3.45%
Virtus LifeSci Biotech Products ETF
2.21%
Franklin Genomic Advancements ETF
2.18%
SPDR S&P Pharmaceuticals ETF
2.12%
Invesco S&P SmallCap Health Care ETF
1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.31%
iShares U.S. Pharmaceuticals ETF
1.25%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
OneAscent Small Cap Core ETF
0.62%
Mehr Anzeigen
Invesco Pharmaceuticals ETF
Anteil3.45%
Virtus LifeSci Biotech Products ETF
Anteil2.21%
Franklin Genomic Advancements ETF
Anteil2.18%
SPDR S&P Pharmaceuticals ETF
Anteil2.12%
Invesco S&P SmallCap Health Care ETF
Anteil1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.31%
iShares U.S. Pharmaceuticals ETF
Anteil1.25%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.8%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil0.77%
OneAscent Small Cap Core ETF
Anteil0.62%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
